Merck Gives Consumer Health Care Division Direct Line To CEO
This article was originally published in The Tan Sheet
Executive Summary
Merck is searching for an executive to lead its new consumer health care division to international growth once its $41.1 billion merger with Schering-Plough closes
You may also be interested in...
Merck Looks To “Exploit” Switches With Exit From J&J Joint Venture
Merck gains flexibility to pursue Rx-to-OTC switches, such as allergy drug Clarinex and cholesterol treatment Zetia by exiting its OTC joint venture with Johnson & Johnson.
Rx-to-OTC Switch Interest Explodes Following Deal Activity - Experts
Pharmaceutical firms are developing and reshaping their Rx-to-OTC switch strategies to remain competitive in an evolving industry where recent mergers and acquisitions underscore the importance of an OTC presence and switch platform
Pharma Firms Stir OTC Market, FDA Hones Enforcement: Top Stories Of 2009
Firms entering or expanding their presence in the OTC drug and nutritional product markets as part of pharmaceutical industry shuffling in 2009 attracted the attention of stakeholders already competing in those markets